Shuttle Pharmaceuticals Secures Funding to Advance radiation Therapy Enhancement Research
Gaithersburg, MD – june 24, 2025 – Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced the accomplished completion of a private placement, bolstering its financial position to accelerate the development of innovative therapies designed to improve cancer treatment outcomes. The company, dedicated to enhancing the efficacy of radiation therapy (RT), aims to address a critical need in oncology by minimizing side effects and maximizing the curative potential of this widely used treatment modality.
Addressing the Limitations of Radiation Therapy
Radiation therapy remains a cornerstone of cancer treatment, utilized in approximately 60% of cancer cases, according to the american cancer Society.However, its effectiveness is often limited by the inherent challenge of delivering a sufficient dose to eradicate cancer cells while concurrently protecting surrounding healthy tissues. This delicate balance frequently results in debilitating side effects,impacting patients’ quality of life and,in some instances,necessitating treatment interruption.
Shuttle Pharma is tackling this challenge head-on through the development of radiation sensitizers – compounds designed to make cancer cells more vulnerable to radiation’s effects. Instead of simply increasing the radiation dose, which exacerbates side effects, thes sensitizers aim to amplify the treatment’s impact at existing dosage levels. This approach mirrors the strategy of using adjuvants in antibiotic therapy, where a secondary medication enhances the primary drug’s effectiveness without increasing its inherent toxicity.
Funding Details and Strategic Allocation
The recently closed private placement involved the sale of pre-funded warrants. These warrants provide the company with immediate capital while offering investors potential future participation in the company’s growth. The proceeds from this financing will be strategically allocated to several key areas, including:
Advancement of Lead compound: Continued preclinical and potentially early-stage clinical development of Shuttle Pharma’s lead radiation sensitizer candidate.
Expansion of Research Pipeline: Exploration and development of additional novel compounds with the potential to enhance radiation therapy’s effectiveness.
* Operational Infrastructure: Strengthening the company’s research and development capabilities and supporting overall operational growth.
Looking Ahead: Improving Cancer Care Through Innovation
“This funding is a notable milestone for Shuttle Pharma, enabling us to aggressively pursue our mission of improving the lives of cancer patients,” stated Chris Cooper, Chief Executive Officer of Shuttle Pharmaceuticals. “By focusing on radiation sensitizers, we believe we can unlock the full potential of RT, leading to higher cure rates, prolonged survival, and a better quality of life for individuals battling this disease.”
The company’s research is especially relevant given the projected increase in cancer incidence globally. The World Health Organization estimates that cancer cases will rise by 50% to nearly 35 million by 2050. Improving existing treatment modalities like radiation therapy is thus paramount to meeting this growing challenge.
Crucial Legal Disclaimer
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any sale of securities must comply with applicable securities laws and regulations.
About Shuttle Pharmaceuticals
Shuttle Pharma is a specialty pharmaceutical company committed to discovering and developing therapies that optimize radiation therapy for cancer patients. The company’s goal is to enhance treatment outcomes by maximizing the effectiveness of RT while minimizing its associated side effects, ultimately improving patient survival and well-being. Further information is available at www.shuttlepharma.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future expectations, plans, and prospects. These statements are subject to various risks and uncertainties, and actual results may differ materially.Factors that could cause such differences are detailed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and other SEC filings.Shuttle Pharma disclaims any obligation to update these forward-looking statements.
contact Information
Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
shph@lythampartners.com